SEBI Reg. Investment Advisor

Download App
Help Center Pricing
Money Works 4 Me Logo MoneyWorks4Me
Talk to Advisor
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

Onyx Biotec Ltd (ONYX)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 0 NSE: ONYX Pharmaceuticals & Drugs | Small Cap | Onyx Biotec Share Price

BSE Share Price
Not Listed

Onyx Biotec Ltd (ONYX)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 0 NSE: ONYX Pharmaceuticals & Drugs | Small Cap | Onyx Biotec Share Price

BSE Share Price
Not Listed
Key Metrics
Valuation Multiples
Market Cap
₹78 Cr.
Current Price
₹0
52-Week Low / High
₹0 / 0
TTM EPS
₹-0.1
TTM Sales
₹69.5 Cr.
Book Value per Share
₹30.7
P/E Ratio
0.00
Lower than its 5-year historical median
Industry PE
46.5
Price to Book (P/B)
1.40
Lower than its 5-year historical median
Price to Sales (P/S)
1.12
Lower than its 5-year historical median
EV/EBITDA
21.29
Higher than its 5-year historical median
Dividend Yield
0.00%
Profitability Efficiency
Return on Equity (ROE)
12.25%
Outperforms industry median
Return on Capital Employed (ROCE)
13.68%
Outperforms industry median
Return on Assets (ROA)
5.99%
Operating Profit Margin
16.7%
Net Profit Margin
8%
Gross Profit Margin
15.4%
Growth Momentum
1-yr vs 3-yr growth
Sales Growth (1 Year)
Improving versus 3-year growth rate
15.26%
Operating Profit Growth (1 Year)
Improving versus 3-year growth rate
23.6%
Net Profit Growth (1 Year)
Improving versus 3-year growth rate
36.36%
Asset Quality
Promoter Holding
65.10%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹37 Cr.
Equity
₹18.1 Cr.
Face Value
₹10
All Time Low / High
- / -

Onyx Biotec stock performance

Key Ratios
mw4me loader

Check Before You Invest

Check Before You Invest

M-Cap below 100cr DeciZen not available

Q.1 Is Onyx Biotec Ltd a good quality company?
Onyx Biotec Ltd is a quality company, based on a multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

View More

We have analysed the performance of the company on the following:

  • How has it performed on generating Profits?

    By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.

  • How efficiently has it utilized Capital?

    By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.

  • How is it managing its Debt?

    By checking its Debt to Equity and Cash Flow from Operations.

View More
How does Onyx Biotec Ltd performance compare with that of its Peers?
Q.1 Revenue growth of Onyx Biotec Ltd vs industry peers?
Onyx Biotec Ltd revenue CAGR is 11.36%, compared to the industry median CAGR of 6.81%, indicating faster growth and gaining its market share.
Q.1 Promoter shareholding and pledge status of Onyx Biotec Ltd?
Promoters hold 65.10% of the Onyx Biotec Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Q.1 Stock return of Onyx Biotec Ltd over the last decade?
Over the last 1 year(s), the stock has delivered a CAGR of -41.83% based on the current price.
View More

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Onyx Biotec Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation ⓘ

Mar'22Mar'23Mar'24Mar'25TTM
ROCE % ⓘ15.5%8.2%12.9%13.7%-
Value Creation
Index ⓘ		0.1-0.4-0.10.0-

Growth Parameters ⓘ
Sales ⓘ44.939.553.86269
Sales YoY Gr.--12%36.1%15.3%-
Adj EPS ⓘ2.81.62.72.4-0.1
YoY Gr.--44.7%73.9%-13.6%-
BVPS (₹) ⓘ13.915.41930.730.7
Adj Net
Profit ⓘ		3.41.93.64.3-0
Cash Flow from Ops. ⓘ0.56.21.51.4-
Debt/CF from Ops. ⓘ25.24.720.38.8-

CAGR ⓘ

9 Years 5 Years 3 Years 1 Years
Sales ⓘNANA11.4%15.3%
Adj EPS ⓘNANA-6%-13.6%
BVPSⓘNANA30.3%61.6%
Share Price - - - -11.7%

Key Financial Parameters ⓘ

Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity % ⓘ		20.510.716.710.6-0.4
Op. Profit
Mgn % ⓘ		12.911.415.616.7NAN
Net Profit
Mgn % ⓘ		7.54.76.86.9-0.3
Debt to
Equity ⓘ		0.81.61.20.2-
Working Cap
Days ⓘ		01471542090
Cash Conv.
Cycle ⓘ		04941740

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'22Mar'23Mar'24Mar'25
Sales44.8639.4853.7561.95
Operating Expenses ⓘ + 39.0934.9945.3651.58
Manufacturing Costs1.421.121.111.01
Material Costs26.5221.0235.7439.13
Employee Cost 8.6210.485.948.64
Other Costs ⓘ 2.532.372.572.79
Operating Profit ⓘ 5.774.498.3910.37
Operating Profit Margin (%) 12.9%11.4%15.6%16.7%
Other Income ⓘ + 0.120.120.131.17
Exceptional Items ⓘ 0000
Interest ⓘ 0.650.572.162.02
Depreciation ⓘ 1.451.491.873.05
Profit Before Tax ⓘ 3.802.554.496.48
Tax ⓘ 0.440.700.861.52
Profit After Tax 3.351.843.634.95
PAT Margin (%) 7.5%4.7%6.8%8.0%
Adjusted EPS (₹)2.81.62.72.7
Dividend Payout Ratio (%)0%0%0%0%

Valuation of Onyx Biotec - Standalone

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Analyst's Notes

data not found
No data found!

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund + 16.3818.2025.2955.62
Share Capital ⓘ 5.905.9013.3218.13
Reserves ⓘ 10.4712.3011.9737.49
Debt +9.8725.3126.5210.85
Long Term Debt8.6318.0223.596.76
Short Term Debt1.247.302.924.10
Minority Interest0000
Trade Payables4.326.9213.7916.73
Others Liabilities ⓘ 6.278.298.558.04
Total Liabilities ⓘ 36.8458.7274.1491.25

Fixed Assets

Net Fixed Assets ⓘ +17.2342.5043.4840.90
Gross Block30.3356.9243.4840.90
Accumulated Depreciation13.0914.4100
CWIP ⓘ 4.02000
Investments ⓘ 0000
Inventories3.056.339.1016.10
Trade Receivables8.425.0815.3720.23
Cash Equivalents 0.010.011.478.61
Others Assets ⓘ 4.104.814.725.40
Total Assets ⓘ 36.8458.7274.1491.25

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity ⓘ + 0.496.241.521.42
PBT ⓘ 3.802.554.496.48
Adjustment ⓘ 2.142.094.064.60
Changes in Working Capital ⓘ -5.451.6-7.03-9.66
Tax Paid ⓘ 0000
Cash Flow From Investing Activity ⓘ + -5.78-22.67-3.150.66
Capex -5.79-22.74-3.220.48
Net Investments 0000
Others ⓘ 0.010.070.070.17
Cash Flow From Financing Activity ⓘ + 5.2016.433.095.07
Net Proceeds from Shares ⓘ 003.6525.38
Net Proceeds from Borrowing ⓘ 3.239.395.58-16.83
Interest Paid ⓘ -0.51-0.55-2.11-1.99
Dividend Paid ⓘ 0000
Others ⓘ 2.487.60-4.02-1.49
Net Cash Flow ⓘ -0.09-0.011.467.15

Financial Ratio

PARTICULARSMar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)20.4710.6716.7112.25
ROCE (%)15.528.2112.8513.68
Asset Turnover Ratio1.220.830.810.75
PAT to CFO Conversion(x)0.153.390.420.29
Working Capital Days
Receivable Days68.5062.4069.40104.90
Inventory Days24.8043.4052.4074.20
Payable Days59.4097.60105.70142.30

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.00
* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Onyx Biotec Ltd FAQs

The current trading price of Onyx Biotec on 01-Jan-1970 05:30 is ₹0.00.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 31-Dec-1969 the market cap of Onyx Biotec stood at ₹77.97 Cr

The latest P/E ratio of Onyx Biotec as of 31-Dec-1969 is 0.00.

The latest P/B ratio of Onyx Biotec as of 31-Dec-1969 is 1.40.

The 52-week high of Onyx Biotec is ₹0.00 and the 52-week low is ₹0.00.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Onyx Biotec is ₹69.47 ( Cr.) .

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Onyx Biotec Ltd is a below average quality company.

The key valuation ratios of Onyx Biotec Ltd's currently when compared to its past seem to suggest it is in the Fair zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Onyx Biotec Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

About Onyx Biotec Ltd

Onyx Biotec Limited was incorporated on May 13, 2005 as a private limited company as ‘Onyx Biotec Private Limited’, under the Companies Act, 1956, pursuant to a certificate of incorporation dated May 13, 2005 issued by the Registrar of Companies, Punjab, H.P. & Chandigarh. Further, the company was converted into a public limited company pursuant to a resolution passed by its Board of Directors in its meeting held on May 1, 2024, and by the Shareholders in an Extraordinary General Meeting held on May 27, 2024 and consequently the name of the company was changed to ‘Onyx Biotec Limited’ and a fresh certificate of incorporation dated July 23, 2024 was issued by the Registrar of Companies, Central Processing Centre.

The company started its operation in pharmaceutical industry with sterile water for injections in the year 2010. Since then, the company has been associated with the healthcare segment and offering Sterile Pharmaceutical products and has become a prominent supplier of sterile products to major corporations, which includes the top pharma companies at pan India level. It is committed to provide high-quality products at affordable price. Also, the company manufactures Sterile Water for Injections, and acts as a pharmaceutical contract manufacturer offering a comprehensive range of Dry Powder Injections and Dry Syrup for India and overseas. 

Its products are being processed and manufactured in accordance with best Food and Drug Administration (FDA) practices available globally. Its system and product are tested constantly at each level to ensure international standards of quality in-house and FDA Certified Laboratories. Its core business is focused on providing end-to-end product development and manufacturing solutions to its clients. Its service also include preparation and filing of regulatory dossiers in the Indian and global markets. Its manufacturing units are equipped with Modern Equipment, ensures Quality Control and follows Sustainable Practices. Its manufacturing units have been accredited by global regulatory agency i.e. World Health Organization Good Manufacturing Practice (WHO-GMP). 

Business area of the company

The company is engaged in the business of Manufacturing of Pharmaceutical Products such as sterile water ampoule, dry injection, dry syrup etc.

Products of the company 

  • Sterile water for injections
  • Dry powder injections
  • Dry powder syrups

History and milestones

  • 2010: The company commenced commercial production at its Unit I with two line of Form Fill and Seal setup with capacity of 2 lakh units per day.
  • 2017: Capacity expansion at its Unit I from 130 million unit per annum to 230 million units per annum. 
  • 2017: The company received a certificate for Good Manufacturing Practice from Deputy Drugs Controller cum Licensing Authority, Health & Family.
  • 2023: The company commenced commercial production at its Unit II. 

To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
2026 ©The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me® is a registered trademark of The Alchemists Ark Pvt. Ltd.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×